trending Market Intelligence /marketintelligence/en/news-insights/trending/eii9weqoueka5wjjtdhprq2 content esgSubNav
In This List

Another Evofem exec joins Daré Bioscience

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Another Evofem exec joins Daré Bioscience

Daré Bioscience Inc. appointed David Friend to the newly created role of chief scientific officer.

The San Diego-based biopharmaceutical company, which is focused on women's health, said Friend is the former chief scientific officer of Evofem Biosciences Inc., a San Diego-based biopharmaceutical company which also focused on women's sexual and reproductive health products.

Prior to Evofem, he served as director of product development at CONRAD, an organization engaged in contraceptive research and drug development. CONRAD/Eastern Virginia Medical School is the principal investigator site in Daré's ongoing clinical trial of Ovaprene, a contraceptive.

Daré Bioscience said Friend's expertise was directly relevant to its portfolio of women's health product candidates, which also includes SST-6007, a potential treatment for female sexual arousal disorder.

The news comes nearly a month after the company appointed John Fair to the newly created position of chief business officer. Fair is the former president and COO of Evofem Biosciences.